Abstract
Introduction Liver cancer is the only cancer in Australia for which mortality rates have consistently risen, despite tests to identify high-risk individuals. Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. Curative treatment for HCC is typically only available if detected early. Australian clinical guidelines recommend routine 6-monthly ultrasound surveillance, with or without serum alpha-fetoprotein, for individuals with liver cirrhosis. This study assesses the health and economic implications of this recommendation, utilizing novel modeling techniques.
Methods We designed the sojourn time density model mathematical framework to develop a model of the evolving risk of HCC, liver disease, and death based on time since diagnosis, incorporating data on liver decompensation, HCC incidence, and HCC survival, and the impact of surveillance on cancer stage and survival.
Results We estimated that adherence to 6-monthly ultrasound, with or without alpha-fetoprotein, can increase early-stage diagnosis rates, reducing HCC mortality by 22%. We estimate a cost-effectiveness ratio of $33,850 per quality-adjusted life-year (QALY) saved for 6-monthly ultrasound HCC surveillance, under the $50,000/QALY cost-effectiveness threshold. HCC surveillance was also estimated to be cost-effective at any interval from 3-24 months.
Conclusions These findings support the current clinical guideline recommendation for 6-monthly ultrasound surveillance, affirming its health benefits and cost-effectiveness, and show that alternative surveillance intervals would remain beneficial and cost-effective. Our model may be used to refine surveillance recommendations for other at-risk population subgroups and inform evidence-based clinical practice recommendations, and the framework can be adapted for other epidemiological modelling. Supporting the clinical guidelines and their ongoing development as evidence evolves may be key to reversing increasing HCC mortality rates in Australia, which are predicted to increase by more than 20% by 2040.
Competing Interest Statement
Karen Canfell is co-principal investigator (PI) of an investigator-initiated trial of HPV screening in Australia (Compass), which is conducted and funded by the Australian Centre for the Prevention of Cervical Cancer (ACPCC), a government-funded health promotion charity. The ACPCC has previously received equipment and a funding contribution for the Compass trial from Roche Molecular Systems USA. She is also co-PI on a major implementation program, "Elimination of Cervical Cancer in the Western Pacific", which receives support from the Minderoo Foundation and equipment donations from Cepheid Inc. Michael Caruana is an investigator on an investigator-initiated trial of cytology and primary HPV screening in Australia ('Compass') (ACTRN12613001207707 and NCT02328872), which is conducted and funded by the Australian Centre for the Prevention of Cervical Cancer, a government-funded health promotion charity. Australian Centre for the Prevention of Cervical Cancer has received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and operational support from the Australian Government. However, neither MC nor his institution on his behalf (the Daffodil Centre, a joint venture between Cancer Council NSW and The University of Sydney) receive direct or indirect funding from industry for Compass Australia.
Funding Statement
Cancer Council Australia financially supported this study as part of the Optimising Liver Cancer Control in Australia project, which was funded through the Australian Government Department of Health and Aged Care. These funding agreements ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript. The modelling in this manuscript is informed by the parameters listed in the appendix.
